The Medipattern Corporation

The Medipattern Corporation

November 22, 2007 11:43 ET

Medipattern B-CAD™ to be Made Available in Canada

B-CAD™ to be distributed by Osiris Medical Inc.

TORONTO, ONTARIO--(Marketwire - Nov. 22, 2007) -

Attention: Business/Financial Editors:

The Medipattern Corporation (TSX VENTURE:MKI), an award-winning developer of computer-aided detection (CAD) medical imaging software designed to aid physicians in making better informed biopsy decisions and to permit a higher standard of care for the millions of patients at risk of breast cancer, is pleased to announce an agreement with Osiris Medical Inc. (Osiris) for distribution of B-CAD in Canada.

Osiris is a distributor of high-quality diagnostic ultrasound imaging systems in the radiology, cardiology, and surgical markets. Osiris' network of regionally focused sales and applications professionals offer customer support at a local level across Canada. Osiris is the exclusive Canadian distributor for Siemens Worldwide Ultrasound Group. Its employees are well-versed in all aspects of the ultrasound business and their skills bring more than 160 years of combined knowledge to the "Canadian" health care market.

"With our long-term partnership with Siemens Acuson Ultrasound, we provide a one-stop solution for the very best in high-quality premium digital imaging systems and accessories. We see B-CAD as a natural fit to the business we conduct across Canada", said Nick Hoffmann, President of Osiris Medical Inc. "Medipattern's software provides useful clinical information and seamless integration into ultrasound systems, culminating in a detailed report that captures all the relevant information for patient treatment or follow-up."

"Nick and the team at Osiris provide Medipattern with an exceptional knowledge of the Canadian healthcare market and in particular the ultrasound market. Their focus and dedication to the sales, service, and support of ultrasound is a natural fit for our B-CAD product," commented Jeff Collins, CEO of The Medipattern Corporation. "We welcome Osiris to our growing family of resellers worldwide and look forward to working with them on the integration of B-CAD into their extensive network of customers across Canada."

Upcoming Events:

Medipattern will participate in the following events:

- Radiological Society of North America (RSNA) booth 5515, November 25 to 29, 2007, Chicago, IL.

- European Congress of Radiology, March 7 to 11, Vienna, Austria

The Medipattern Corporation

Medipattern develops computer-aided detection (CAD) solutions for medical imaging. These products enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical applications are B-CAD™ for breast ultrasound and B-CADMRI™. Both have received awards for innovation in the industry. The B-CAD products use pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in images of the breast. Medipattern was founded to design software products that detect and identify lesions in breast imaging to support a higher standard of medical care. Please visit the company's website at:

B-CAD™ and B-CADMRI™ are trademarks of The Medipattern Corporation.
Medipattern® is a registered mark of The Medipattern Corporation. BI-RADS® is a registered trademark of the American College of Radiology.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates", "believes", "estimates", "expects", "plans", "intends", "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.

Contact Information